VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: squetch who wrote (1563)	7/7/1997 4:43:00 PM
From: Pseudo Biologist	of 9719

squetch, I am still not bored enough, but I did a bit of reading on this. First, the company, Alfacell (ACEL), looks sad. It may be a case of being too early in the field before many of the bugs, conceptual and otherwise, have been worked out. This is my impression after a very superficial analysis. On onconase itself, the concept is intriguing and it may be a new way of treating cancer. It does not seem to have much in the way of specificity, but it may have advantages over standard chemotherapy. The fact that this is a frog protein surely does not endear it to WS or to big pharma. It may be possible to "humanize" this molecule as human ribonuclease and ribonuclease-like molecules do exist and one can think of being able to engineer an effective "hybrid protein." Some of the work of RJ Youle (at times with ACEL people) suggests that this engineering is not totally out of the question. An interesting review of ribonucleases, including Onconase, just appeared in Nature Biotechnology of June 1997 (by Catherine Schein of U Texas - Galveston e-mail werner@nmr.utmb.edu for info or a reprint). Hope this helps some, PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next